REDWOOD CITY, Calif., Jan. 04, 2021 (GLOBE NEWSWIRE) — Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that management will present a corporate overview at the H.C. Wainwright Virtual BioConnect 2021 Conference, being held January 11-14, 2021.
The presentation will be available on-demand beginning on Monday, January 11, 2021, in the Investors section on the Company’s website at www.soleno.life.
About Soleno Therapeutics, Inc.
Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company’s lead candidate, Diazoxide Choline Controlled-Release (DCCR) tablets, a once-daily oral tablet for the treatment of Prader-Willi Syndrome (PWS), is currently being evaluated in a Phase III clinical development program. For more information, please visit www.soleno.life.
Corporate Contact:
Brian Ritchie
LifeSci Advisors, LLC
212-915-2578
SINGAPORE, Oct. 8, 2025 /PRNewswire/ -- Neopharma Technologies Ltd ("Neopharma"), a digital health company pioneering…
Data from 700+ healthcare leaders and 1,000+ practices shows measurable gains in revenue recovery, staff…
New CMO, EVP Operations and SVP Clinical Solutions bring track records of scalable growth and…
LAKE OSWEGO, Ore., Oct. 8, 2025 /PRNewswire/ -- AYUMETRIX, an early innovator for modern, at-home…
BOSTON, Oct. 8, 2025 /PRNewswire/ -- eschbach, developer of Shiftconnector®, an intelligent operations platform for…
JERSEY CITY, N.J., Oct. 8, 2025 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of…
![](data:image/svg+xml;charset=utf-8,<svg height="32px" width="32px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
![](data:image/svg+xml;charset=utf-8,<svg height="1px" width="1px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
